Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.14 1.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.1400000000000001

Põhinäitajad
By Trading Economics
Sissetulek	-2.3M -22M
Aktsiakasum	-0.36
Töötajad	49
EBITDA	-2.4M -22M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+115.52% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. nov 2026

Turustatistika
By TradingEconomics
Turukapital	3.7M 68M
Eelmine avamishind	-0.65
Eelmine sulgemishind	1.14

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. aug 2026, 23:51 UTC

RBA Meeting Minutes Release on August 25, 2026, Sparks Cautious Market Sentiment Amid Persistent Inflation and Economic Cooling in Australia.

22. aug 2026, 23:51 UTC

Macro News

Bitcoin is trading lower during Saturday's session, despite earlier rising above $70,000, amid ongoing geopolitical tensions and pressures in the bond market.

22. aug 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields raise concerns over economic growth and investor sentiment shifts towards safer assets.

22. aug 2026, 23:41 UTC

Cryptocurrency Prices Drop Amid Rising Bond Yields and Geopolitical Tensions, Impacting Market Sentiment.

22. aug 2026, 23:41 UTC

Cryptocurrency Markets Decline Amid Rising Bond Yields and Economic Pressures, with Ethereum Down 3.9% and Bitcoin 1.7%.

22. aug 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields and inflation concerns pressure risk assets amid mixed global market performance.

22. aug 2026, 23:41 UTC

U.S. Goods Trade Balance Expected to Show $99 Billion Deficit Amidst Rising Tariff Tensions with Canada

22. aug 2026, 23:41 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Expected to Impact Market Sentiment Amid Cautious Investor Outlook.

22. aug 2026, 23:41 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% Amid Caution Over Economic Conditions and Market Volatility

22. aug 2026, 23:41 UTC

Canada's Current Account Deficit Expected to Widen to -5.5 Billion CAD Amid Trade Negotiation Uncertainties with the U.S.

22. aug 2026, 23:41 UTC

Terra is trading lower today, reversing three consecutive sessions of gains. The asset has declined significantly since Friday's close, with no specific news identified.

22. aug 2026, 23:31 UTC

US GDP Price Index QoQ 2nd Estimate on August 26 Forecasts 0.063% Increase Amid Rising Oil Prices and Optimistic Q3 Growth Outlook

22. aug 2026, 23:31 UTC

South Africa's Balance of Trade Data Set for Release Amidst Investor Optimism Following Recent Surplus Growth and Global Economic Pressures.

22. aug 2026, 23:31 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Mixed Economic Sentiment and Market Volatility

22. aug 2026, 23:21 UTC

Market braces for July 2026 PCE Price Index release, with a modest +0.1% increase forecast amid mixed inflation sentiment and external economic pressures.

22. aug 2026, 23:21 UTC

PCE Price Index Release on August 26, 2026: Key Inflation Indicator Amid Market Volatility and Fed Policy Concerns.

22. aug 2026, 23:21 UTC

U.S. Personal Income Expected to Rise 0.3% in August Amid Cautious Market Sentiment and Consumer Spending Concerns

22. aug 2026, 23:21 UTC

U.S. Personal Spending Forecasted to Rise 0.2% in August Amid Mixed Economic Signals and Inflation Concerns

22. aug 2026, 23:21 UTC

Core PCE Price Index MoM for July 2026 set to release on August 26, with a forecasted increase of 0.2%, amid rising oil prices and geopolitical tensions influencing market sentiment.

22. aug 2026, 23:21 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.5% Amid Economic Caution and Upcoming Market Influences

22. aug 2026, 23:21 UTC

U.S. Durable Goods Orders Expected to Rise 0.7% Amid Economic Volatility and Geopolitical Tensions, with Market Cautiously Optimistic Ahead of Jackson Hole Symposium

22. aug 2026, 23:21 UTC

U.S. GDP Growth Rate Expected at +1.5% for Q2 2026 Amid Optimistic Economic Indicators and Fed's Revised Forecast of +2.3% for Q3

22. aug 2026, 23:21 UTC

U.S. Corporate Profits Report for Q2 2026 Set to Release Amid Economic Uncertainty and Market Volatility on August 26.

22. aug 2026, 23:11 UTC

ECB Meeting Accounts Set for Release Amid Market Anticipation of Interest Rate Signals and Inflation Trends on August 27, 2026.

22. aug 2026, 23:11 UTC

Mexico's Trade Balance Expected to Show Continued Surplus Amid U.S.-Canada Negotiation Uncertainty Ahead of August 27 Data Release.

22. aug 2026, 23:11 UTC

Brazil's Unemployment Rate Set for Release Amid Optimistic Market Sentiment Following June Drop to 5.4%

22. aug 2026, 23:11 UTC

News

Ethereum is lower today, continuing a decline since Friday's close. Earlier, the asset reached a session low before recovering slightly.

22. aug 2026, 23:11 UTC

Correlated Moves

Avalanche is declining today, influenced by a drop in correlated asset Ethereum. The asset's recent strong performance contrasts with today's downturn during the session.

22. aug 2026, 23:11 UTC

News

Ethereum is lower during Saturday's session, reflecting a significant drop since Friday's close. The asset reached a session low earlier today.

22. aug 2026, 23:01 UTC

Macro News

The DAX 30 Index is declining after the U.S. imposed 50% tariffs on Canadian goods, worsening trade relations and impacting investor sentiment.

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

115.52% tõus

12 kuu keskmine prognoos

Keskmine 2.5 USD 115.52%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.